QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Forecast, Price & News

$1.09
0.00 (0.00%)
(As of 09/21/2023 ET)
Compare
Today's Range
$1.05
▼
$1.11
50-Day Range
$1.06
▼
$1.43
52-Week Range
$1.01
▼
$2.03
Volume
74,366 shs
Average Volume
172,111 shs
Market Capitalization
$41.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesShort InterestSocial Media

Bolt Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
419.9% Upside
$5.67 Price Target
Short Interest
Bearish
6.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.03) to ($1.89) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

329th out of 961 stocks

Pharmaceutical Preparations Industry

144th out of 448 stocks

See Top Rated MarketRank™ Stocks Here

BOLT stock logo

About Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

BOLT Price History

BOLT Stock News Headlines

September 18, 2023 | americanbankingnews.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 12.3% in August
September 5, 2023 | finance.yahoo.com
Bolt Biotherapeutics to Participate in September Investor Conferences
September 21, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
August 3, 2023 | msn.com
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
June 17, 2023 | finance.yahoo.com
US0977021049.SG - Bolt Biotherapeutics Inc.
May 26, 2023 | markets.businessinsider.com
Bolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright
May 13, 2023 | msn.com
SVB Leerink Upgrades Bolt Biotherapeutics (BOLT)
May 13, 2023 | msn.com
HC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy Recommendation
September 21, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 12, 2023 | markets.businessinsider.com
JonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)
May 12, 2023 | finanznachrichten.de
Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
April 26, 2023 | finance.yahoo.com
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
April 11, 2023 | finance.yahoo.com
Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year
March 30, 2023 | finanznachrichten.de
Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 14, 2023 | finance.yahoo.com
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
January 21, 2023 | reuters.com
BOLT.O - | Stock Price & Latest News | Reuters
January 4, 2023 | finance.yahoo.com
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation
November 2, 2022 | finance.yahoo.com
Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year
November 1, 2022 | finance.yahoo.com
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
September 10, 2022 | morningstar.com
Bolt Biotherapeutics Inc Ordinary Shares
August 31, 2022 | finance.yahoo.com
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
August 12, 2022 | benzinga.com
Bolt Biotherapeutics (NASDAQ:BOLT), Earnings Estimates, EPS, and Revenue
May 26, 2022 | finance.yahoo.com
The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable
March 30, 2022 | finance.yahoo.com
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 30, 2022 | seekingalpha.com
Bolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51M
March 8, 2022 | finance.yahoo.com
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
February 10, 2022 | finance.yahoo.com
Bolt Biotherapeutics, Inc. (BOLT)
See More Headlines
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BOLT Company Calendar

Last Earnings
8/07/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BOLT
CUSIP
09769810
CIK
354655
Web
www.boltbio.com
Phone
650-665-9295
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+419.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-88,100,000.00
Net Margins
-1,132.31%
Pretax Margin
-1,132.31%
Return on Equity
-46.56%
Return on Assets
-35.30%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
7.42
Quick Ratio
7.42

Sales & Book Value

Annual Sales
$5.73 million
Price / Sales
7.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.55 per share
Price / Book
0.24

Miscellaneous

Outstanding Shares
37,950,000
Free Float
27,173,000
Market Cap
$41.37 million
Optionable
Not Optionable
Beta
0.90
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Randall C. Schatzman Ph.D. (Age 68)
    CEO & Director
    Comp: $829.32k
  • Dr. Edgar George Engleman M.D. (Age 77)
    Founder & Independent Director
    Comp: $38.75k
  • Mr. William P. QuinnMr. William P. Quinn (Age 52)
    CFO & Sec.
    Comp: $594.56k
  • Mr. Grant Yonehiro C.F.A. (Age 59)
    M.B.A., Chief Bus. Officer
    Comp: $544.71k
  • Dr. Edith A. Perez M.D. (Age 66)
    Chief Medical Officer
    Comp: $668.32k
  • Ms. Karen L. Bergman
    VP of Communications & Investor Relations
  • Mr. Wesley Burwell
    VP & Head of HR
  • Dr. Nathan Ihle Ph.D.
    Sr. VP of Pharmaceutical Operations
  • Dr. Ming Yin Ph.D.
    VP & Head of Biometrics

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













BOLT Stock - Frequently Asked Questions

Should I buy or sell Bolt Biotherapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BOLT shares.
View BOLT analyst ratings or view top-rated stocks.

What is Bolt Biotherapeutics' stock price forecast for 2023?

3 brokerages have issued 1-year price objectives for Bolt Biotherapeutics' stock. Their BOLT share price forecasts range from $3.00 to $8.00. On average, they anticipate the company's share price to reach $5.67 in the next year. This suggests a possible upside of 419.9% from the stock's current price.
View analysts price targets for BOLT or view top-rated stocks among Wall Street analysts.

How have BOLT shares performed in 2023?

Bolt Biotherapeutics' stock was trading at $1.30 at the beginning of 2023. Since then, BOLT stock has decreased by 16.2% and is now trading at $1.09.
View the best growth stocks for 2023 here.

Are investors shorting Bolt Biotherapeutics?

Bolt Biotherapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 1,500,000 shares, a decline of 12.3% from the August 15th total of 1,710,000 shares. Based on an average daily volume of 93,400 shares, the days-to-cover ratio is presently 16.1 days. Currently, 6.4% of the shares of the stock are sold short.
View Bolt Biotherapeutics' Short Interest.

When is Bolt Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BOLT earnings forecast.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its earnings results on Monday, August, 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.05. The company had revenue of $1.43 million for the quarter, compared to analyst estimates of $1.69 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 46.56% and a negative net margin of 1,132.31%.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP).

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

Who are Bolt Biotherapeutics' major shareholders?

Bolt Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (7.87%), Renaissance Technologies LLC (1.28%), Geode Capital Management LLC (0.93%), BlackRock Inc. (0.76%), Assenagon Asset Management S.A. (0.42%) and JPMorgan Chase & Co. (0.34%). Insiders that own company stock include Edgar Engleman, Holdings A/S Novo, Randall C Schatzman, Vivo Capital Fund Viii, LP and William P Quinn.
View institutional ownership trends.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $1.09.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics (NASDAQ:BOLT) has a market capitalization of $41.37 million and generates $5.73 million in revenue each year. The company earns $-88,100,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.boltbio.com. The company can be reached via phone at 650-665-9295 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:BOLT) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -